Payment overview · 2025
General Payments
$512.02
18 reported records · 11 companies
Healthcare provider profile · identity verified
Sumana Ketha, MD
Allopathic & Osteopathic Physicians|Internal Medicine · IRVING, TX · NPI 1962447805
Verified facts
What the public records show
CMS Open Payments records show Sumana Ketha, MD received $512.02 in general payments during 2025 across 18 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $162.58 | 31.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.70 | 17.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.06 | 10.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.09 | 9.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.52 | 7.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.56 | 5.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.83 | 4.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.08 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.31 | 3.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.88 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.41 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $512.02 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $162.58 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.06 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.09 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.55 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $31.29 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.56 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 133 |
| Gabapentin | Gabapentin | 401 | 95 |
| Metformin Hcl | Metformin Hcl | 367 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 66 |
| Lisinopril | Lisinopril | 315 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 266 | 43 |
| Losartan Potassium | Losartan Potassium | 266 | 76 |
| Furosemide | Furosemide | 259 | 68 |
| Omeprazole | Omeprazole | 224 | 56 |
| Eliquis | Apixaban | 210 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 45 |
| Trazodone Hcl | Trazodone Hcl | 175 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 41 |
| Carvedilol | Carvedilol | 163 | 44 |
| Donepezil Hcl | Donepezil Hcl | 153 | 30 |
| Levetiracetam | Levetiracetam | 153 | 30 |
| Memantine Hcl | Memantine Hcl | 143 | 27 |
| Divalproex Sodium | Divalproex Sodium | 138 | 28 |
| Jardiance | Empagliflozin | 135 | 22 |
| Potassium Chloride | Potassium Chloride | 132 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 34 |
| Sertraline Hcl | Sertraline Hcl | 125 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 124 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 28 |
| Meloxicam | Meloxicam | 100 | 33 |
| Farxiga | Dapagliflozin Propanediol | 96 | 21 |
| Mirtazapine | Mirtazapine | 93 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 26 |
| Simvastatin | Simvastatin | 90 | 27 |
| Allopurinol | Allopurinol | 89 | 17 |
| Ozempic | Semaglutide | 89 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 27 |
| Tramadol Hcl | Tramadol Hcl | 87 | 38 |
| Montelukast Sodium | Montelukast Sodium | 85 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 28 |
| Trulicity | Dulaglutide | 85 | 26 |
| Latanoprost | Latanoprost | 78 | 14 |
| Baclofen | Baclofen | 75 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 25 |
| Nifedipine Er | Nifedipine | 72 | 23 |
| Buspirone Hcl | Buspirone Hcl | 70 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 61 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 14 |
| Alprazolam | Alprazolam | 58 | 11 |
| Ibuprofen | Ibuprofen | 58 | 23 |
| Januvia | Sitagliptin Phosphate | 58 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 16 |
| Gemtesa | Vibegron | 55 | suppressed |
| Glimepiride | Glimepiride | 53 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 23 |
| Lactulose | Lactulose | 49 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 14 |
| Alendronate Sodium | Alendronate Sodium | 45 | 11 |
| Methylprednisolone | Methylprednisolone | 45 | 42 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 26 |
| Azithromycin | Azithromycin | 43 | 36 |
| Finasteride | Finasteride | 43 | 12 |
| Pregabalin | Pregabalin | 42 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Famotidine | Famotidine | 38 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 11 |
| Metformin Hcl Er | Metformin Hcl | 38 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Risperidone | Risperidone | 35 | 12 |
| Amoxicillin | Amoxicillin | 34 | 25 |
| Enulose | Lactulose | 32 | suppressed |
| Glipizide | Glipizide | 32 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Naproxen | Naproxen | 31 | 14 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | 12 |
| Nystatin | Nystatin | 28 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 18 |
| Nystop | Nystatin | 26 | 11 |
| Clonidine Hcl | Clonidine Hcl | 25 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Nyamyc | Nystatin | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | 14 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Renvela | Sevelamer Carbonate | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $512.02 · 18 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, Kerendia, OFEV, Ozempic, PREVNAR 20, REXULTI, TZIELD, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error